{"product_id":"acp105-60x10mg","title":"ACP-105 100x10mg","description":"\u003cp class=\"\" data-end=\"936\" data-start=\"448\"\u003e\u003cstrong data-end=\"459\" data-start=\"448\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                         \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"936\" data-start=\"448\"\u003e\u003cstrong data-end=\"459\" data-start=\"448\"\u003eACP-105\u003c\/strong\u003e is a novel, selective androgen receptor modulator (\u003cstrong data-end=\"519\" data-start=\"511\"\u003eSARM\u003c\/strong\u003e) initially developed by Acadia Pharmaceuticals. It has gained attention primarily due to its potential anabolic effects on muscle and bone tissues, combined with minimal androgenic side effects typically associated with traditional anabolic steroids. ACP-105 remains experimental, with promising preclinical results indicating therapeutic potential for muscle wasting, osteoporosis, and certain endocrine conditions.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"941\" data-start=\"938\"\u003e\n\u003ch2 class=\"\" data-end=\"980\" data-start=\"943\"\u003eChemical and Biological Properties\u003c\/h2\u003e\n\u003cul data-end=\"1225\" data-start=\"982\"\u003e\n\u003cli class=\"\" data-end=\"1010\" data-start=\"982\"\u003e\n\u003cp class=\"\" data-end=\"1010\" data-start=\"984\"\u003e\u003cstrong data-end=\"1002\" data-start=\"984\"\u003eChemical Name:\u003c\/strong\u003e ACP-105\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1081\" data-start=\"1011\"\u003e\n\u003cp class=\"\" data-end=\"1081\" data-start=\"1013\"\u003e\u003cstrong data-end=\"1023\" data-start=\"1013\"\u003eClass:\u003c\/strong\u003e Nonsteroidal Selective Androgen Receptor Modulator (SARM)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1225\" data-start=\"1082\"\u003e\n\u003cp class=\"\" data-end=\"1225\" data-start=\"1084\"\u003e\u003cstrong data-end=\"1109\" data-start=\"1084\"\u003eAdministration Route:\u003c\/strong\u003e Primarily oral, providing convenient systemic administration with potential selectivity for muscle and bone tissue.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"1230\" data-start=\"1227\"\u003e\n\u003ch2 class=\"\" data-end=\"1254\" data-start=\"1232\"\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"1330\" data-start=\"1256\"\u003eACP-105 functions through selective modulation of androgen receptors (AR):\u003c\/p\u003e\n\u003ch3 class=\"\" data-end=\"1375\" data-start=\"1332\"\u003e1. Tissue-Selective Androgenic Activity\u003c\/h3\u003e\n\u003cul data-end=\"1595\" data-start=\"1376\"\u003e\n\u003cli class=\"\" data-end=\"1468\" data-start=\"1376\"\u003e\n\u003cp class=\"\" data-end=\"1468\" data-start=\"1378\"\u003ePotent agonist of AR, exhibiting anabolic activity selectively in muscle and bone tissues.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1595\" data-start=\"1469\"\u003e\n\u003cp class=\"\" data-end=\"1595\" data-start=\"1471\"\u003eMinimal activation of AR in tissues such as the prostate and seminal vesicles, thus reducing common androgenic side effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"1639\" data-start=\"1597\"\u003e2. Anabolic and Anti-Catabolic Effects\u003c\/h3\u003e\n\u003cul data-end=\"1876\" data-start=\"1640\"\u003e\n\u003cli class=\"\" data-end=\"1745\" data-start=\"1640\"\u003e\n\u003cp class=\"\" data-end=\"1745\" data-start=\"1642\"\u003ePromotes muscle growth and hypertrophy by enhancing protein synthesis and reducing protein degradation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1876\" data-start=\"1746\"\u003e\n\u003cp class=\"\" data-end=\"1876\" data-start=\"1748\"\u003eProtects muscle and bone tissue from wasting and degradation, particularly beneficial in cachexia, osteoporosis, and sarcopenia.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"1906\" data-start=\"1878\"\u003e3. Improved Bone Density\u003c\/h3\u003e\n\u003cul data-end=\"2006\" data-start=\"1907\"\u003e\n\u003cli class=\"\" data-end=\"2006\" data-start=\"1907\"\u003e\n\u003cp class=\"\" data-end=\"2006\" data-start=\"1909\"\u003eIncreases bone mineral density, potentially useful in treating osteoporosis or fracture recovery.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2011\" data-start=\"2008\"\u003e\n\u003ch2 class=\"\" data-end=\"2067\" data-start=\"2013\"\u003ePotential Therapeutic and Experimental Applications\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"2148\" data-start=\"2069\"\u003eACP-105 has primarily been researched experimentally in the following contexts:\u003c\/p\u003e\n\u003ch3 class=\"\" data-end=\"2186\" data-start=\"2150\"\u003e1. Muscle Wasting and Sarcopenia\u003c\/h3\u003e\n\u003cul data-end=\"2432\" data-start=\"2187\"\u003e\n\u003cli class=\"\" data-end=\"2306\" data-start=\"2187\"\u003e\n\u003cp class=\"\" data-end=\"2306\" data-start=\"2189\"\u003eShown significant anabolic potential in preventing muscle atrophy and promoting muscle growth in preclinical studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2432\" data-start=\"2307\"\u003e\n\u003cp class=\"\" data-end=\"2432\" data-start=\"2309\"\u003ePotential therapeutic candidate for muscle-wasting conditions such as cachexia (associated with chronic diseases or aging).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2469\" data-start=\"2434\"\u003e2. Osteoporosis and Bone Health\u003c\/h3\u003e\n\u003cul data-end=\"2690\" data-start=\"2470\"\u003e\n\u003cli class=\"\" data-end=\"2580\" data-start=\"2470\"\u003e\n\u003cp class=\"\" data-end=\"2580\" data-start=\"2472\"\u003eDemonstrated promising results in increasing bone mineral density and strength in preclinical rodent models.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2690\" data-start=\"2581\"\u003e\n\u003cp class=\"\" data-end=\"2690\" data-start=\"2583\"\u003ePotentially valuable as an alternative or adjunctive treatment for osteoporosis or recovery from fractures.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2735\" data-start=\"2692\"\u003e3. Hormone Replacement and Hypogonadism\u003c\/h3\u003e\n\u003cul data-end=\"2909\" data-start=\"2736\"\u003e\n\u003cli class=\"\" data-end=\"2909\" data-start=\"2736\"\u003e\n\u003cp class=\"\" data-end=\"2909\" data-start=\"2738\"\u003eExperimental interest in ACP-105 as a potential alternative to traditional testosterone replacement therapy (TRT), providing anabolic benefits with fewer androgenic risks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"2965\" data-start=\"2911\"\u003e4. Athletic Performance Enhancement (Experimental)\u003c\/h3\u003e\n\u003cul data-end=\"3143\" data-start=\"2966\"\u003e\n\u003cli class=\"\" data-end=\"3143\" data-start=\"2966\"\u003e\n\u003cp class=\"\" data-end=\"3143\" data-start=\"2968\"\u003eAnecdotally explored in performance enhancement contexts to promote lean muscle mass, improve strength, and enhance recovery with fewer side effects than traditional steroids.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"3148\" data-start=\"3145\"\u003e\n\u003ch2 class=\"\" data-end=\"3201\" data-start=\"3150\"\u003eDosage and Administration (Experimental Context)\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3375\" data-start=\"3203\"\u003eACP-105 is not approved by any regulatory agency; thus, standardized human dosing guidelines do not exist. Based on limited anecdotal experimental use, typical dosages are:\u003c\/p\u003e\n\u003cul data-end=\"3695\" data-start=\"3377\"\u003e\n\u003cli class=\"\" data-end=\"3453\" data-start=\"3377\"\u003e\n\u003cp class=\"\" data-end=\"3453\" data-start=\"3379\"\u003e\u003cstrong data-end=\"3408\" data-start=\"3379\"\u003eExperimental Oral Dosage:\u003c\/strong\u003e 5–20 mg\/day, most commonly around 10 mg\/day.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3560\" data-start=\"3454\"\u003e\n\u003cp class=\"\" data-end=\"3560\" data-start=\"3456\"\u003e\u003cstrong data-end=\"3485\" data-start=\"3456\"\u003eAdministration Frequency:\u003c\/strong\u003e Usually taken once daily due to oral bioavailability and pharmacokinetics.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3695\" data-start=\"3561\"\u003e\n\u003cp class=\"\" data-end=\"3695\" data-start=\"3563\"\u003e\u003cstrong data-end=\"3595\" data-start=\"3563\"\u003eExperimental Cycle Duration:\u003c\/strong\u003e Typically administered experimentally for 4–8 weeks, followed by breaks or discontinuation periods.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"3812\" data-start=\"3697\"\u003e\u003cstrong data-end=\"3706\" data-start=\"3697\"\u003eNote:\u003c\/strong\u003e These dosages reflect anecdotal experimental practices; rigorous clinical dosing data remain unavailable.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"3817\" data-start=\"3814\"\u003e\n\u003ch2 class=\"\" data-end=\"3853\" data-start=\"3819\"\u003eSafety Profile and Side Effects\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3950\" data-start=\"3855\"\u003eDue to the limited number of human studies, safety data for ACP-105 remain largely preclinical:\u003c\/p\u003e\n\u003ch3 class=\"\" data-end=\"4021\" data-start=\"3952\"\u003eCommonly Reported Side Effects (Rare and Mild Anecdotal Reports):\u003c\/h3\u003e\n\u003cul data-end=\"4237\" data-start=\"4022\"\u003e\n\u003cli class=\"\" data-end=\"4060\" data-start=\"4022\"\u003e\n\u003cp class=\"\" data-end=\"4060\" data-start=\"4024\"\u003eMild headaches or transient fatigue.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4194\" data-start=\"4061\"\u003e\n\u003cp class=\"\" data-end=\"4194\" data-start=\"4063\"\u003eMinor suppression of natural testosterone production (common with SARMs, but reportedly less severe compared to anabolic steroids).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4237\" data-start=\"4195\"\u003e\n\u003cp class=\"\" data-end=\"4237\" data-start=\"4197\"\u003eMild gastrointestinal discomfort (rare).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"4279\" data-start=\"4239\"\u003ePotential Long-term Safety Concerns:\u003c\/h3\u003e\n\u003cul data-end=\"4501\" data-start=\"4280\"\u003e\n\u003cli class=\"\" data-end=\"4413\" data-start=\"4280\"\u003e\n\u003cp class=\"\" data-end=\"4413\" data-start=\"4282\"\u003eLimited data regarding long-term effects, particularly relating to endocrine disruption, cardiovascular impacts, or liver function.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4501\" data-start=\"4414\"\u003e\n\u003cp class=\"\" data-end=\"4501\" data-start=\"4416\"\u003eNo data available on potential carcinogenic risks or reproductive toxicity in humans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"4506\" data-start=\"4503\"\u003e\n\u003ch2 class=\"\" data-end=\"4544\" data-start=\"4508\"\u003eContraindications and Precautions\u003c\/h2\u003e\n\u003cul data-end=\"4917\" data-start=\"4546\"\u003e\n\u003cli class=\"\" data-end=\"4702\" data-start=\"4546\"\u003e\n\u003cp class=\"\" data-end=\"4571\" data-start=\"4548\"\u003e\u003cstrong data-end=\"4570\" data-start=\"4548\"\u003eContraindications:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"4702\" data-start=\"4574\"\u003e\n\u003cli class=\"\" data-end=\"4626\" data-start=\"4574\"\u003e\n\u003cp class=\"\" data-end=\"4626\" data-start=\"4576\"\u003ePregnancy and breastfeeding due to unknown safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4702\" data-start=\"4629\"\u003e\n\u003cp class=\"\" data-end=\"4702\" data-start=\"4631\"\u003eHistory of hormone-sensitive cancers (e.g., prostate or breast cancer).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4917\" data-start=\"4704\"\u003e\n\u003cp class=\"\" data-end=\"4722\" data-start=\"4706\"\u003e\u003cstrong data-end=\"4722\" data-start=\"4706\"\u003ePrecautions:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"4917\" data-start=\"4725\"\u003e\n\u003cli class=\"\" data-end=\"4815\" data-start=\"4725\"\u003e\n\u003cp class=\"\" data-end=\"4815\" data-start=\"4727\"\u003ePotential suppression of endogenous testosterone; monitoring hormone levels recommended.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"4917\" data-start=\"4818\"\u003e\n\u003cp class=\"\" data-end=\"4917\" data-start=\"4820\"\u003eIndividuals with pre-existing liver, renal, or cardiovascular conditions should exercise caution.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"4922\" data-start=\"4919\"\u003e\n\u003ch2 class=\"\" data-end=\"4954\" data-start=\"4924\"\u003eLegal and Regulatory Status\u003c\/h2\u003e\n\u003cul data-end=\"5295\" data-start=\"4956\"\u003e\n\u003cli class=\"\" data-end=\"5085\" data-start=\"4956\"\u003e\n\u003cp class=\"\" data-end=\"5085\" data-start=\"4958\"\u003e\u003cstrong data-end=\"4982\" data-start=\"4958\"\u003eRegulatory Approval:\u003c\/strong\u003e ACP-105 is not approved by regulatory authorities (FDA, EMA, Health Canada) for human therapeutic use.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5192\" data-start=\"5086\"\u003e\n\u003cp class=\"\" data-end=\"5192\" data-start=\"5088\"\u003eCurrently classified and sold exclusively as a \"research chemical,\" labeled \"not for human consumption.\"\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5295\" data-start=\"5193\"\u003e\n\u003cp class=\"\" data-end=\"5295\" data-start=\"5195\"\u003eExplicitly banned by World Anti-Doping Agency (WADA) due to potential performance-enhancing effects.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"5300\" data-start=\"5297\"\u003e\n\u003ch2 class=\"\" data-end=\"5341\" data-start=\"5302\"\u003eCurrent Research Status and Evidence\u003c\/h2\u003e\n\u003cul data-end=\"5974\" data-start=\"5343\"\u003e\n\u003cli class=\"\" data-end=\"5499\" data-start=\"5343\"\u003e\n\u003cp class=\"\" data-end=\"5371\" data-start=\"5345\"\u003e\u003cstrong data-end=\"5370\" data-start=\"5345\"\u003ePreclinical Research:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"5499\" data-start=\"5374\"\u003e\n\u003cli class=\"\" data-end=\"5499\" data-start=\"5374\"\u003e\n\u003cp class=\"\" data-end=\"5499\" data-start=\"5376\"\u003eAnimal studies indicate potent anabolic and bone-protective properties with favorable tissue-selective androgenic profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5753\" data-start=\"5501\"\u003e\n\u003cp class=\"\" data-end=\"5530\" data-start=\"5503\"\u003e\u003cstrong data-end=\"5529\" data-start=\"5503\"\u003eHuman Clinical Trials:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"5753\" data-start=\"5533\"\u003e\n\u003cli class=\"\" data-end=\"5630\" data-start=\"5533\"\u003e\n\u003cp class=\"\" data-end=\"5630\" data-start=\"5535\"\u003eNo large-scale human clinical trials available; research primarily preclinical and exploratory.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5753\" data-start=\"5633\"\u003e\n\u003cp class=\"\" data-end=\"5753\" data-start=\"5635\"\u003eClinical data are urgently needed to establish definitive efficacy, safety, dosing guidelines, and clinical potential.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5974\" data-start=\"5755\"\u003e\n\u003cp class=\"\" data-end=\"5793\" data-start=\"5757\"\u003e\u003cstrong data-end=\"5792\" data-start=\"5757\"\u003eLimitations and Research Needs:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"5974\" data-start=\"5796\"\u003e\n\u003cli class=\"\" data-end=\"5874\" data-start=\"5796\"\u003e\n\u003cp class=\"\" data-end=\"5874\" data-start=\"5798\"\u003eLack of human safety and efficacy data from well-controlled clinical trials.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"5974\" data-start=\"5877\"\u003e\n\u003cp class=\"\" data-end=\"5974\" data-start=\"5879\"\u003eNeed for long-term studies to evaluate chronic safety, endocrine effects, and systemic impacts.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"5979\" data-start=\"5976\"\u003e\n\u003ch2 class=\"\" data-end=\"6023\" data-start=\"5981\"\u003eSummary of Potential Benefits and Risks\u003c\/h2\u003e\n\u003cdiv class=\"group pointer-events-none relative flex justify-center *:pointer-events-auto\"\u003e\n\u003cspan data-state=\"closed\" class=\"pointer-events-none absolute start-full top-4 z-10 hidden h-full w-fit ps-2 md:block\"\u003e\u003cbutton class=\"hover:bg-token-main-surface-secondary text-token-text-secondary pointer-events-auto rounded-lg px-1 py-1 opacity-0 transition-opacity duration-200 group-focus-within:opacity-100 group-hover:opacity-100\"\u003e\u003csvg class=\"icon-md-heavy\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" fill=\"none\" viewbox=\"0 0 24 24\" height=\"24\" width=\"24\"\u003e\u003cpath fill=\"currentColor\" d=\"M7 5C7 3.34315 8.34315 2 10 2H19C20.6569 2 22 3.34315 22 5V14C22 15.6569 20.6569 17 19 17H17V19C17 20.6569 15.6569 22 14 22H5C3.34315 22 2 20.6569 2 19V10C2 8.34315 3.34315 7 5 7H7V5ZM9 7H14C15.6569 7 17 8.34315 17 10V15H19C19.5523 15 20 14.5523 20 14V5C20 4.44772 19.5523 4 19 4H10C9.44772 4 9 4.44772 9 5V7ZM5 9C4.44772 9 4 9.44772 4 10V19C4 19.5523 4.44772 20 5 20H14C14.5523 20 15 19.5523 15 19V10C15 9.44772 14.5523 9 14 9H5Z\" clip-rule=\"evenodd\" fill-rule=\"evenodd\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/button\u003e\u003c\/span\u003e\n\u003cdiv class=\"tableContainer horzScrollShadows relative\"\u003e\n\u003ctable data-end=\"6668\" data-start=\"6025\" class=\"min-w-full\"\u003e\n\u003cthead data-end=\"6128\" data-start=\"6025\"\u003e\n\u003ctr data-end=\"6128\" data-start=\"6025\"\u003e\n\u003cth data-end=\"6071\" data-start=\"6025\"\u003e\u003cstrong data-end=\"6049\" data-start=\"6027\"\u003ePotential Benefits\u003c\/strong\u003e\u003c\/th\u003e\n\u003cth data-end=\"6128\" data-start=\"6071\"\u003e\u003cstrong data-end=\"6108\" data-start=\"6073\"\u003ePotential Risks and Limitations\u003c\/strong\u003e\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-end=\"6668\" data-start=\"6234\"\u003e\n\u003ctr data-end=\"6337\" data-start=\"6234\"\u003e\n\u003ctd data-end=\"6280\" data-start=\"6234\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)]\"\u003eMuscle growth and strength enhancement\u003c\/td\u003e\n\u003ctd data-end=\"6337\" data-start=\"6280\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)]\"\u003eLack of human clinical safety data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6441\" data-start=\"6338\"\u003e\n\u003ctd data-end=\"6384\" data-start=\"6338\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003ePrevention of muscle wasting and sarcopenia\u003c\/td\u003e\n\u003ctd data-end=\"6441\" data-start=\"6384\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003ePotential suppression of natural testosterone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6545\" data-start=\"6442\"\u003e\n\u003ctd data-end=\"6488\" data-start=\"6442\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eImproved bone density and fracture recovery\u003c\/td\u003e\n\u003ctd data-end=\"6545\" data-start=\"6488\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eUnclear long-term endocrine and systemic safety risks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-end=\"6668\" data-start=\"6546\"\u003e\n\u003ctd data-end=\"6611\" data-start=\"6546\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eSelective anabolic activity with fewer androgenic side effects\u003c\/td\u003e\n\u003ctd data-end=\"6668\" data-start=\"6611\" class=\"max-w-[calc(var(--thread-content-max-width)*2\/3)] min-w-[calc(var(--thread-content-max-width)\/3)]\"\u003eRegulatory uncertainty and legal restrictions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr class=\"\" data-end=\"6673\" data-start=\"6670\"\u003e\n\u003ch2 class=\"\" data-end=\"6714\" data-start=\"6675\"\u003eFuture Directions and Research Needs\u003c\/h2\u003e\n\u003cul data-end=\"7079\" data-start=\"6716\"\u003e\n\u003cli class=\"\" data-end=\"6826\" data-start=\"6716\"\u003e\n\u003cp class=\"\" data-end=\"6826\" data-start=\"6718\"\u003eRigorous human clinical trials to confirm therapeutic efficacy, determine optimal dosing, and assess safety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"6928\" data-start=\"6827\"\u003e\n\u003cp class=\"\" data-end=\"6928\" data-start=\"6829\"\u003eLong-term safety evaluations focused on endocrine, cardiovascular, hepatic, and carcinogenic risks.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"7079\" data-start=\"6929\"\u003e\n\u003cp class=\"\" data-end=\"7079\" data-start=\"6931\"\u003eExploration of ACP-105’s clinical potential in muscle-wasting diseases, osteoporosis, hormone replacement therapy, and related endocrine conditions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"7084\" data-start=\"7081\"\u003e\n\u003ch2 class=\"\" data-end=\"7099\" data-start=\"7086\"\u003eConclusion\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"7680\" data-start=\"7101\"\u003eACP-105 is a promising experimental SARM exhibiting potent anabolic activity in muscle and bone tissues with minimal androgenic side effects in preclinical studies. Despite the therapeutic potential indicated by preliminary animal data and anecdotal human reports, significant gaps remain, including lack of robust clinical trials, uncertainty regarding long-term safety, and regulatory restrictions. Individuals interested in experimental use of ACP-105 should proceed cautiously, recognizing its current status as an unapproved research compound with limited human safety data.\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"7685\" data-start=\"7682\"\u003e\n\u003ch2 class=\"\" data-end=\"7720\" data-start=\"7687\"\u003eReferences \u003c\/h2\u003e\n\u003cul data-end=\"8339\" data-start=\"7722\"\u003e\n\u003cli class=\"\" data-end=\"7919\" data-start=\"7722\"\u003e\n\u003cp class=\"\" data-end=\"7919\" data-start=\"7724\"\u003eVajda, E. G., et al. (2009). \"Pharmacokinetics and pharmacodynamics of ACP-105, a novel nonsteroidal selective androgen receptor modulator.\" \u003cem data-end=\"7899\" data-start=\"7865\"\u003eJournal of Clinical Pharmacology\u003c\/em\u003e, 49(10), 1196–1206.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"8069\" data-start=\"7920\"\u003e\n\u003cp class=\"\" data-end=\"8069\" data-start=\"7922\"\u003eGao, W., et al. (2005). \"Preclinical profile of ACP-105, a novel selective androgen receptor modulator (SARM).\" \u003cem data-end=\"8049\" data-start=\"8034\"\u003eEndocrinology\u003c\/em\u003e, 146(9), 4235–4244.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"8252\" data-start=\"8070\"\u003e\n\u003cp class=\"\" data-end=\"8252\" data-start=\"8072\"\u003eSolomon, Z. J., \u0026amp; Mirkin, S. (2008). \"Selective androgen receptor modulators: Current knowledge and clinical applications.\" \u003cem data-end=\"8234\" data-start=\"8196\"\u003eMolecular and Cellular Endocrinology\u003c\/em\u003e, 289(1-2), 42–48.\u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"8672\" data-start=\"8346\"\u003e \u003c\/p\u003e\n\u003cp class=\"\" data-end=\"8672\" data-start=\"8346\"\u003e\u003cstrong data-end=\"8361\" data-start=\"8346\"\u003eDisclaimer:\u003c\/strong\u003e\u003cbr data-end=\"8364\" data-start=\"8361\"\u003eThis comprehensive review is provided exclusively for educational purposes. ACP-105 is an experimental research compound and is \u003cstrong data-end=\"8508\" data-start=\"8492\"\u003enot approved\u003c\/strong\u003e by health regulatory authorities for therapeutic human use. Always consult qualified healthcare providers before considering experimental compounds or supplements.\u003c\/p\u003e","brand":"Mijn winkel","offers":[{"title":"Default Title","offer_id":52684866191698,"sku":null,"price":75.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/ACP-105_10mg.png?v=1770834946","url":"https:\/\/sciencepeptideslab.com\/products\/acp105-60x10mg","provider":"Science Peptides Lab","version":"1.0","type":"link"}